The U.S. Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP) issues warning letters to Outlook Pharmaceuticals as there was a sponsored Google link that did not include any risk information for its treatment for attention deficit disorder with hyperactivity.

The warning also notes that the company failed to present the established name for ProCentra (i.e. dextroamphetamine sulfate) in the ad, thereby misbranding the product. OPDP said the FDA Bad Ad Program also received complaints regarding this sponsored link on Google.